NXT629
- Generic Name
- NXT629
A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy
Phase 3
Not yet recruiting
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Tempest Therapeutics
- Target Recruit Count
- 740
- Registration Number
- NCT06680258
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
Phase 1
Recruiting
- Conditions
- Advanced Liver Cancers
- Interventions
- Drug: IO-108 1800 mgDrug: Tobemstomig 2100 mgDrug: Tobemstomig 600 mgDrug: Tobemstomig 1200 mgDrug: IO-108 1200 mg
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 518
- Registration Number
- NCT04524871
- Locations
- 🇮🇱
Hadassah University Medical Center, Jerusalem, Israel
🇰🇷CHA Bundang Medical Center, Gyeonggi-do, Korea, Republic of
🇺🇸University of California San Diego, La Jolla, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath